6-K 1 f6k_020226.htm FORM 6-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

January 31, 2026

________________

 

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F ☒           Form 40-F ☐

  

 
 

 

 

 

 

 

 

New employee representative on the Board of Directors of Novo Nordisk A/S

 

 

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since 2018, has decided to pursue new opportunities outside Novo Nordisk A/S after 22 years of employment. Therefore, he steps down from the Board of Directors and his alternate, Tanja Villumsen, joins the Board of Directors of Novo Nordisk A/S as employee representative with effect from today.

 

 

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,500 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

 

 

Contacts for further information:

 

 

Media:  
Ambre James-Brown Liz Skrbkova (US)
+45 3079 9289 +1 609 917 0632
globalmedia@novonordisk.com lzsk@novonordisk.com
   
   
Investors:  
Michael Novod Jacob Martin Wiborg Rode
+45 3075 6050 +45 3075 5956
nvno@novonordisk.com jrde@novonordisk.com
   
Max Ung Sina Meyer
+45 3077 6414 +45 3079 6656
mxun@novonordisk.com azey@novonordisk.com
   
   
   

 

 

 

 

 

Alex Bruce Christoffer Sho Togo Tullin
+45 34 44 26 13 +45 3079 1471
axeu@novonordisk.com cftu@novonordisk.com
   
Frederik Taylor Pitter  
+1 609 613 0568  
fptr@novonordisk.com  

 

 

 

 

 

 

 

 

 

 

 

Novo Nordisk A/S

Investor Relations

Novo Alle 1

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

www.novonordisk.com
CVR no: 24 25 67 90

   Company announcement No 1 / 2026

 

 
 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: February 2, 2026

 

NOVO NORDISK A/S

 

Maziar Mike Doustdar

Chief Executive Officer